Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 2
1965 1
1967 1
1969 3
1970 1
1972 1
1973 3
1974 3
1977 1
1986 1
1989 1
1990 2
1995 1
1998 4
1999 1
2000 1
2001 1
2002 1
2003 2
2004 2
2006 4
2007 4
2008 2
2009 3
2010 4
2011 8
2012 4
2013 8
2014 8
2015 9
2016 17
2017 7
2018 21
2019 15
2020 29
2021 20
2022 22
2023 22
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

223 results

Results by year

Filters applied: . Clear all
Page 1
Treating cancer with selective CDK4/6 inhibitors.
O'Leary B, Finn RS, Turner NC. O'Leary B, et al. Nat Rev Clin Oncol. 2016 Jul;13(7):417-30. doi: 10.1038/nrclinonc.2016.26. Epub 2016 Mar 31. Nat Rev Clin Oncol. 2016. PMID: 27030077 Review.
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study.
Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean MJ, Turner NC. Cristofanilli M, et al. Among authors: o leary b. Clin Cancer Res. 2022 Aug 15;28(16):3433-3442. doi: 10.1158/1078-0432.CCR-22-0305. Clin Cancer Res. 2022. PMID: 35552673 Free PMC article. Clinical Trial.
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial.
O'Leary B, Cutts RJ, Liu Y, Hrebien S, Huang X, Fenwick K, André F, Loibl S, Loi S, Garcia-Murillas I, Cristofanilli M, Huang Bartlett C, Turner NC. O'Leary B, et al. Cancer Discov. 2018 Nov;8(11):1390-1403. doi: 10.1158/2159-8290.CD-18-0264. Epub 2018 Sep 11. Cancer Discov. 2018. PMID: 30206110 Free PMC article. Clinical Trial.
The Oncologist of the Future.
O'Leary B, Yeoh K. O'Leary B, et al. Clin Oncol (R Coll Radiol). 2022 Sep;34(9):578-580. doi: 10.1016/j.clon.2022.03.018. Epub 2022 Apr 14. Clin Oncol (R Coll Radiol). 2022. PMID: 35431120 No abstract available.
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Fribbens C, O'Leary B, Kilburn L, Hrebien S, Garcia-Murillas I, Beaney M, Cristofanilli M, Andre F, Loi S, Loibl S, Jiang J, Bartlett CH, Koehler M, Dowsett M, Bliss JM, Johnston SR, Turner NC. Fribbens C, et al. Among authors: o leary b. J Clin Oncol. 2016 Sep 1;34(25):2961-8. doi: 10.1200/JCO.2016.67.3061. Epub 2016 Jun 6. J Clin Oncol. 2016. PMID: 27269946 Clinical Trial.
Epigenetic effects of pharmacologic ascorbate.
Steers GJ, Carroll RS, O'Leary BR, Cullen JJ. Steers GJ, et al. Among authors: o leary br. Oncotarget. 2021 Apr 27;12(9):876-877. doi: 10.18632/oncotarget.27911. eCollection 2021 Apr 27. Oncotarget. 2021. PMID: 33953841 Free PMC article. No abstract available.
Discovering marine biodiversity in the 21st century.
Rogers AD, Appeltans W, Assis J, Ballance LT, Cury P, Duarte C, Favoretto F, Hynes LA, Kumagai JA, Lovelock CE, Miloslavich P, Niamir A, Obura D, O'Leary BC, Ramirez-Llodra E, Reygondeau G, Roberts C, Sadovy Y, Steeds O, Sutton T, Tittensor DP, Velarde E, Woodall L, Aburto-Oropeza O. Rogers AD, et al. Among authors: o leary bc. Adv Mar Biol. 2022;93:23-115. doi: 10.1016/bs.amb.2022.09.002. Epub 2022 Nov 7. Adv Mar Biol. 2022. PMID: 36435592 Review.
223 results